Bioelectronics: the origin of the idea

Moncef Slaoui, Chairman, Global R&D and Vaccines, and Kris Famm, VP, Bioelectronics R&D discuss the origin of their idea for our bioelectronics program.

GSK's Bioelectronics R&D unit is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturised, implantable devices called bioelectronic medicines. We believe that these devices could be programmed to read and correct the electrical signals that pass along the nerves of the body, including irregular or altered impulses that can occur in association with a broad range of diseases. The hope is that through these devices, disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes could be treated.

Видео Bioelectronics: the origin of the idea канала GSK